PMID: 8602351Feb 1, 1996Paper

Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-alpha by the incorporation of 2'-O-propyl modifications

Nucleic Acids Research
R McKayN Dean

Abstract

We have previously described the characterization of a 20mer phosphorothioate oligodeoxynucleotide (ISIS 4189) which inhibits murine protein kinase C-alpha (PKC-alpha) gene expression, both in vitro and in vivo. In an effort to increase the antisense activity of this oligonucleotide, 2'-O-propyl modifications have been incorporated into the 5'- and 3'-ends of the oligonucleotide, with the eight central bases left as phosphorothioate oligodeoxynucleotides. Hybridization analysis demonstrated that these modifications increased affinity by approximately 8 and 6 degrees C per oligonucleotide for the phosphodiester (ISIS 7815) and phosphorothioate (ISIS 7817) respectively when hybridized to an RNA complement. In addition, 2'-O-propyl incorporation greatly enhanced the nuclease resistance of the oligonucleotides to snake venom phosphodiesterase or intracellular nucleases in vivo. The increase in affinity and nuclease stability of ISIS 7817 resulted in a 5-fold increase in the ability of the oligonucleotide to inhibit PKC-alpha gene expression in murine C127 cells, as compared with the parent phosphorothioate oligodeoxynucleotide. Thus an RNase H-dependent phosphorothioate oligodeoxynucleotide can be modified as a 2'-O-propyl 'chimeri...Continue Reading

References

Apr 1, 1991·Bio/technology·P S Miller
Jan 1, 1992·Annual Review of Pharmacology and Toxicology·S T Crooke
Dec 1, 1991·Pharmacology & Therapeutics·C A SteinL Yakubov
Sep 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·S AgrawalJ Y Tang
Oct 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·A M IribarrenA I Lamond
Feb 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·S AgrawalT Pederson
Mar 1, 1990·Journal of Biochemical and Biophysical Methods·J M CampbellE Wickstrom
Jan 1, 1987·Nucleic Acids Symposium Series·H InoueE Ohtsuka
Apr 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·C BornerD Fabbro
Nov 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·M MatsukuraS Broder
Sep 1, 1986·Journal of Biochemical and Biophysical Methods·E Wickstrom
Aug 11, 1995·Journal of Chromatography. a·G J BruinA Paulus
Nov 22, 1994·Proceedings of the National Academy of Sciences of the United States of America·N M Dean, R McKay

❮ Previous
Next ❯

Citations

Dec 31, 1997·Biochemical Pharmacology·C F Bennett
Nov 25, 1998·Biochemical Pharmacology·K G Waddick, F M Uckun
Aug 24, 1999·Pharmacology & Therapeutics·S R CooperN M Dean
Jan 1, 1997·Molecular Medicine Today·R W Wagner, W M Flanagan
Dec 13, 2002·Antisense & Nucleic Acid Drug Development·Neelima B Chauhan
Sep 5, 2003·Antisense & Nucleic Acid Drug Development·Lijiang ShenBrett P Monia
May 21, 1998·Antisense & Nucleic Acid Drug Development·N M DeanJ Holmlund
Mar 25, 1998·Antisense & Nucleic Acid Drug Development·M GilarA S Cohen
Jul 6, 2014·PloS One·Daniel J HoganDimitrios G Zisoulis
Jul 22, 1997·Proceedings of the National Academy of Sciences of the United States of America·S MorelliA Nicolin
Jan 24, 2003·Expert Opinion on Therapeutic Targets·Margaret F Taylor
Jul 5, 2005·Expert Opinion on Investigational Drugs·C F Bennett
Apr 26, 2006·Expert Opinion on Investigational Drugs·Hideaki MiyakeMartin E Gleave
Oct 6, 2005·International Journal of Urology : Official Journal of the Japanese Urological Association·Hideaki MiyakeMartin E Gleave
Jul 18, 1997·The Journal of Biological Chemistry·W F LimaS T Crooke
Sep 24, 1998·Journal of Chromatography. B, Biomedical Sciences and Applications·M GilarA S Cohen
Oct 1, 1996·Trends in Biotechnology·S Agrawal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.